Drug intelligence / Profile preview

TG-1801 + ublituximab

Development stage: Unknown
Lead developer: TG Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TG-1801 + ublituximab is an investigational combination therapy of two monoclonal antibodies for the treatment of B-cell lymphomas. TG-1801 is a fully human bispecific antibody that simultaneously targets CD19 and CD47, selectively blocking the "do not eat me" signal (CD47) on CD19+ B-cells, promoting antibody-dependent cellular phagocytosis, and depleting malignant B-cells. Ublituximab is a glycoengineered anti-CD20 monoclonal antibody, approved for multiple sclerosis, which binds CD20 on mature B-cells, enabling antibody-dependent cellular cytotoxicity. This combination leverages complementary B-cell-directed and immune-activating mechanisms in B-cell lymphoma, particularly in relapsed/refractory settings. The combination is being developed by TG Therapeutics, with clinical evaluation for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)[1][3][7].

Brand names: Briumvi
Other names: TG 1801TG1801TG-1801ublituximab-xiiy

Targets

CD19 (B lymphocyte antigen CD19)CD47 (Cluster of Differentiation 47)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on TG-1801 + ublituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TG-1801 + ublituximab.

Explore the full profile